The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention

English version České info

In a Perspective for our Collection on STI research, Janneke van de Wijgert discusses the latest on how the vaginal microbiota predisposes women to acquisition of STIs and discusses future potential for clinical intervention.

Vyšlo v časopise: The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. PLoS Med 14(12): e32767. doi:10.1371/journal.pmed.1002478
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002478

Souhrn

Zdroje

1. van de Wijgert JHHM, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS ONE. 2014;9(8):e105998. doi: 10.1371/journal.pone.0105998 25148517

2. Lewis FM, Bernstein KT, Aral SO. Vaginal microbiome and its relationship to behavior, sexual health, and sexually transmitted diseases. Obstet Gynecol. 2017;129(4):643–654. doi: 10.1097/AOG.0000000000001932 28277350

3. Borgdorff H, Gautam R, Armstrong SD, Xia D, Ndayisaba GF, van Teijlingen NH, et al. Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunol. 2015;9(3):621–633. doi: 10.1038/mi.2015.86 26349657

4. van de Wijgert JHHM, Jespers V. The global health impact of vaginal dysbiosis. Res Microbiol. 2017;pii: S0923-2508(17)30038–4. doi: 10.1016/j.resmic.2017.02.003 28257809

5. Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012; 4(132):132ra52. doi: 10.1126/scitranslmed.3003605 22553250

6. Petrova MI, Reid G, Vaneechoutte M, Lebeer S. Lactobacillus iners: friend or foe? Trends Microbiol. 2017;25(3):182–191. doi: 10.1016/j.tim.2016.11.007 27914761

7. Borgdorff H, van der Veer C, van Houdt R, Alberts CJ, de Vries HJ, Bruisten SM, et al. The association between ethnicity and vaginal microbiota composition in Amsterdam, the Netherlands. PLoS ONE. 2017;12(7):e0181135. doi: 10.1371/journal.pone.0181135 28700747

8. van de Wijgert J, Morrison C, Brown J, Kwok C, Van Der Pol B, Chipato T, et al. Disentangling the contributions of reproductive tract infections on HIV acquisition in African women. Sex Transm Dis. 2009;36(6):357–364. doi: 10.1097/OLQ.0b013e3181a4f695 19434010

9. Cools P, Jespers V, Hardy L, Crucitti T, Delany-Moretlwe S, Mwaura M, et al. A multi-country cross-sectional study of vaginal carriage of Group B Streptococci (GBS) and Escherichia coli in resource-poor settings: prevalences and risk factors. PLoS ONE. 2016;11(1):e0148052. doi: 10.1371/journal.pone.0148052 26811897

10. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis—striving for long-term cure. BMC Infect Dis. 2015;15:292. doi: 10.1186/s12879-015-1027-4 26219949

11. Verstraelen H, Verhelst R. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev Anti Infect Ther. 2009;7(9):1109–1124. doi: 10.1586/eri.09.87 19883331

12. Swidsinski A, Mendling W, Loening-Baucke V, Swidsinski S, Dörffel Y, Scholze J, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1–6. doi: 10.1016/j.ajog.2007.06.039 18005928

13. Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5):1283–1289. doi: 10.1016/j.ajog.2005.11.041 16647911

14. van der Eem L, Dubbink JH, Struthers HE, McIntyre JA, Ouburg S, Morré SA, et al. Evaluation of syndromic management guidelines for treatment of sexually transmitted infections in South African women. Trop Med Int Health. 2016;21(9):1138–1146. doi: 10.1111/tmi.12742 27350659